-
Je něco špatně v tomto záznamu ?
Multimodal prediction of neoadjuvant treatment outcome by serial FDG PET and MRI in women with locally advanced breast cancer
AS. Kazerouni, LM. Peterson, I. Jenkins, A. Novakova-Jiresova, HM. Linden, JR. Gralow, DM. Hockenbery, DA. Mankoff, PL. Porter, SC. Partridge, JM. Specht
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, Research Support, N.I.H., Extramural
Grantová podpora
R01 CA248192
NCI NIH HHS - United States
P50 CA138293
NCI NIH HHS - United States
P30 CA015704
NCI NIH HHS - United States
NLK
BioMedCentral
od 1999-12-01
BioMedCentral Open Access
od 1999
Directory of Open Access Journals
od 2000
Free Medical Journals
od 1999 do Před 2 roky
PubMed Central
od 1999
Europe PubMed Central
od 1999
ProQuest Central
od 2015-01-01
Open Access Digital Library
od 1999-07-01
Open Access Digital Library
od 1999-01-01
Open Access Digital Library
od 2000-01-01
Health & Medicine (ProQuest)
od 2015-01-01
ROAD: Directory of Open Access Scholarly Resources
od 1999
Springer Nature OA/Free Journals
od 1999-12-01
- MeSH
- dospělí MeSH
- fluorodeoxyglukosa F18 terapeutické užití MeSH
- lidé MeSH
- magnetická rezonanční tomografie metody MeSH
- nádory prsu * diagnostické zobrazování farmakoterapie MeSH
- neoadjuvantní terapie metody MeSH
- pozitronová emisní tomografie metody MeSH
- prospektivní studie MeSH
- radiofarmaka terapeutické užití MeSH
- výsledek terapie MeSH
- Check Tag
- dospělí MeSH
- lidé MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- Research Support, N.I.H., Extramural MeSH
PURPOSE: To investigate combined MRI and 18F-FDG PET for assessing breast tumor metabolism/perfusion mismatch and predicting pathological response and recurrence-free survival (RFS) in women treated for breast cancer. METHODS: Patients undergoing neoadjuvant chemotherapy (NAC) for locally-advanced breast cancer were imaged at three timepoints (pre, mid, and post-NAC), prior to surgery. Imaging included diffusion-weighted and dynamic contrast-enhanced (DCE-) MRI and quantitative 18F-FDG PET. Tumor imaging measures included apparent diffusion coefficient, peak percent enhancement (PE), peak signal enhancement ratio (SER), functional tumor volume, and washout volume on MRI and standardized uptake value (SUVmax), glucose delivery (K1) and FDG metabolic rate (MRFDG) on PET, with percentage changes from baseline calculated at mid- and post-NAC. Associations of imaging measures with pathological response (residual cancer burden [RCB] 0/I vs. II/III) and RFS were evaluated. RESULTS: Thirty-five patients with stage II/III invasive breast cancer were enrolled in the prospective study (median age: 43, range: 31-66 years, RCB 0/I: N = 11/35, 31%). Baseline imaging metrics were not significantly associated with pathologic response or RFS (p > 0.05). Greater mid-treatment decreases in peak PE, along with greater post-treatment decreases in several DCE-MRI and 18F-FDG PET measures were associated with RCB 0/I after NAC (p < 0.05). Additionally, greater mid- and post-treatment decreases in DCE-MRI (peak SER, washout volume) and 18F-FDG PET (K1) were predictive of prolonged RFS. Mid-treatment decreases in metabolism/perfusion ratios (MRFDG/peak PE, MRFDG/peak SER) were associated with improved RFS. CONCLUSION: Mid-treatment changes in both PET and MRI measures were predictive of RCB status and RFS following NAC. Specifically, our results indicate a complementary relationship between DCE-MRI and 18F-FDG PET metrics and potential value of metabolism/perfusion mismatch as a marker of patient outcome.
American Society of Clinical Oncology Alexandria VA USA
Charles University and Thomayer University Hospital Prague Czech Republic
Department of Radiology University of Pennsylvania Philadelphia PA USA
Department of Radiology University of Washington Fred Hutchinson Cancer Center Seattle WA USA
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24000709
- 003
- CZ-PrNML
- 005
- 20240213093328.0
- 007
- ta
- 008
- 240109s2023 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1186/s13058-023-01722-4 $2 doi
- 035 __
- $a (PubMed)37946201
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Kazerouni, Anum S $u Department of Radiology, University of Washington/Fred Hutchinson Cancer Center, Seattle, WA, USA
- 245 10
- $a Multimodal prediction of neoadjuvant treatment outcome by serial FDG PET and MRI in women with locally advanced breast cancer / $c AS. Kazerouni, LM. Peterson, I. Jenkins, A. Novakova-Jiresova, HM. Linden, JR. Gralow, DM. Hockenbery, DA. Mankoff, PL. Porter, SC. Partridge, JM. Specht
- 520 9_
- $a PURPOSE: To investigate combined MRI and 18F-FDG PET for assessing breast tumor metabolism/perfusion mismatch and predicting pathological response and recurrence-free survival (RFS) in women treated for breast cancer. METHODS: Patients undergoing neoadjuvant chemotherapy (NAC) for locally-advanced breast cancer were imaged at three timepoints (pre, mid, and post-NAC), prior to surgery. Imaging included diffusion-weighted and dynamic contrast-enhanced (DCE-) MRI and quantitative 18F-FDG PET. Tumor imaging measures included apparent diffusion coefficient, peak percent enhancement (PE), peak signal enhancement ratio (SER), functional tumor volume, and washout volume on MRI and standardized uptake value (SUVmax), glucose delivery (K1) and FDG metabolic rate (MRFDG) on PET, with percentage changes from baseline calculated at mid- and post-NAC. Associations of imaging measures with pathological response (residual cancer burden [RCB] 0/I vs. II/III) and RFS were evaluated. RESULTS: Thirty-five patients with stage II/III invasive breast cancer were enrolled in the prospective study (median age: 43, range: 31-66 years, RCB 0/I: N = 11/35, 31%). Baseline imaging metrics were not significantly associated with pathologic response or RFS (p > 0.05). Greater mid-treatment decreases in peak PE, along with greater post-treatment decreases in several DCE-MRI and 18F-FDG PET measures were associated with RCB 0/I after NAC (p < 0.05). Additionally, greater mid- and post-treatment decreases in DCE-MRI (peak SER, washout volume) and 18F-FDG PET (K1) were predictive of prolonged RFS. Mid-treatment decreases in metabolism/perfusion ratios (MRFDG/peak PE, MRFDG/peak SER) were associated with improved RFS. CONCLUSION: Mid-treatment changes in both PET and MRI measures were predictive of RCB status and RFS following NAC. Specifically, our results indicate a complementary relationship between DCE-MRI and 18F-FDG PET metrics and potential value of metabolism/perfusion mismatch as a marker of patient outcome.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a dospělí $7 D000328
- 650 12
- $a nádory prsu $x diagnostické zobrazování $x farmakoterapie $7 D001943
- 650 _2
- $a fluorodeoxyglukosa F18 $x terapeutické užití $7 D019788
- 650 _2
- $a neoadjuvantní terapie $x metody $7 D020360
- 650 _2
- $a radiofarmaka $x terapeutické užití $7 D019275
- 650 _2
- $a prospektivní studie $7 D011446
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a magnetická rezonanční tomografie $x metody $7 D008279
- 650 _2
- $a pozitronová emisní tomografie $x metody $7 D049268
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a Research Support, N.I.H., Extramural $7 D052061
- 700 1_
- $a Peterson, Lanell M $u Division of Hematology and Oncology, University of Washington/Fred Hutchinson Cancer Center, 1144 Eastlake (Mail Stop LG-500), Seattle, WA, 98109-1023, USA
- 700 1_
- $a Jenkins, Isaac $u Fred Hutchinson Cancer Consortium, Seattle, WA, USA
- 700 1_
- $a Novakova-Jiresova, Alena $u Charles University and Thomayer University Hospital, Prague, Czech Republic
- 700 1_
- $a Linden, Hannah M $u Division of Hematology and Oncology, University of Washington/Fred Hutchinson Cancer Center, 1144 Eastlake (Mail Stop LG-500), Seattle, WA, 98109-1023, USA
- 700 1_
- $a Gralow, Julie R $u American Society of Clinical Oncology, Alexandria, VA, USA
- 700 1_
- $a Hockenbery, David M $u Fred Hutchinson Cancer Consortium, Seattle, WA, USA
- 700 1_
- $a Mankoff, David A $u Department of Radiology, University of Pennsylvania, Philadelphia, PA, USA
- 700 1_
- $a Porter, Peggy L $u Fred Hutchinson Cancer Consortium, Seattle, WA, USA
- 700 1_
- $a Partridge, Savannah C $u Department of Radiology, University of Washington/Fred Hutchinson Cancer Center, Seattle, WA, USA
- 700 1_
- $a Specht, Jennifer M $u Division of Hematology and Oncology, University of Washington/Fred Hutchinson Cancer Center, 1144 Eastlake (Mail Stop LG-500), Seattle, WA, 98109-1023, USA. jspecht@uw.edu
- 773 0_
- $w MED00006602 $t Breast cancer research $x 1465-542X $g Roč. 25, č. 1 (2023), s. 138
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37946201 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240109 $b ABA008
- 991 __
- $a 20240213093326 $b ABA008
- 999 __
- $a ok $b bmc $g 2049374 $s 1210403
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 25 $c 1 $d 138 $e 20231109 $i 1465-542X $m Breast cancer research $n Breast Cancer Res $x MED00006602
- GRA __
- $a R01 CA248192 $p NCI NIH HHS $2 United States
- GRA __
- $a P50 CA138293 $p NCI NIH HHS $2 United States
- GRA __
- $a P30 CA015704 $p NCI NIH HHS $2 United States
- LZP __
- $a Pubmed-20240109